Eli Lilly Acquires SiteOne Therapeutics

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

JanOne Inc. Agrees to Acquire Soin Therapeutics LLC

September 16, 2022

Pharmaceuticals

JanOne Inc. has executed a term sheet to acquire Soin Therapeutics LLC and its patent-pending low-dose naltrexone formulation (to be named JAN123) for the treatment of Complex Regional Pain Syndrome (CRPS). The deal is valued at $13 million up front with up to $17 million in additional contingent payments (total up to $30 million); JanOne expects to advance JAN123 into GMP manufacturing and file an IND in 2023.

Eli Lilly and Company to Acquire Orna Therapeutics in Up to $2.4 Billion Deal

February 9, 2026

Biotechnology

Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics in a deal valued at up to $2.4 billion. The acquisition is intended to expand Lilly’s capabilities in genetic medicine and in vivo cell engineering, particularly to advance in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle platform.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Eli Lilly Acquires POINT Biopharma Global

December 27, 2023

Biotechnology

Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.

Servier Acquires Day One Biopharmaceuticals for About $2.5 Billion

March 6, 2026

Pharmaceuticals

Servier entered into a definitive agreement to acquire Day One Biopharmaceuticals, a commercial-stage biopharmaceutical company, in a cash deal valued at about $2.5 billion. Servier will pay $21.50 per share and expects the transaction to close in the second quarter of 2026, subject to customary regulatory approvals and tender conditions.